What You Need to Know
• The Food and Drug Administration approved daraxonrasib, branded as Rasonque, for metastatic pancreatic cancer on Wednesday.
• A clinical trial involving 500 patients indicated that median overall survival increased to over 13 months with daraxonrasib.
• Approximately 95% of exocrine pancreatic cancers in the U.S. are pancreatic adenocarcinoma, which has a high mortality rate.
The Food and Drug Administration (FDA) approved daraxonrasib, a new drug from Revolution Medicines, on Wednesday, which may extend the survival of patients with metastatic pancreatic cancer. This daily pill targets various forms of the RAS protein, a key factor in tumor growth. In a late-stage clinical trial with 500 participants, the median overall survival for patients taking daraxonrasib nearly doubled to more than 13 months compared to about 6.7 months for those receiving standard chemotherapy. Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at the Dana-Farber Cancer Institute, highlighted the approval as a significant milestone for patients and research efforts in targeting KRAS mutations. The FDA had previously granted the drug a “Breakthrough Therapy” designation to expedite its development and review process.
Why It Matters
This approval is significant as pancreatic adenocarcinoma, which constitutes about 3.2% of all cancer diagnoses, leads to a disproportionately high number of cancer-related deaths in the U.S. The disease is often diagnosed late, and treatment options have historically been limited. The FDA’s expedited review process reflects the urgent need for effective therapies in this area of high unmet medical need. The success of daraxonrasib may pave the way for advancements in treating other challenging cancers in the future.
Read the Full Story →
